About KoshKey
KoshKey is a company based in Bengaluru (India) founded in 2022 by Tanay Bhatt and Colin Jamora. The company has 1 employees. KoshKey offers products and services including RNAi Therapy, Skin Biology Services, Histopathology Services, and Virology Services. KoshKey operates in a competitive market with competitors including MiRagen, ProQR Therapeutics, Prosensa, Cardior Pharmaceuticals and Ilya Pharma, among others.
- Headquarter Bengaluru, India
- Employees 1
- Founders Tanay Bhatt, Colin Jamora
- SectorsHealthcare
- Website koshkey.com
- Social LinkedIn X Instagram
- Legal Name Koshkey Sciences Private Limited
- Date of Incorporation 02 May, 2022
- Jurisdiction Bangalore, Karnataka, India
- Annual Revenue₹97.3 Lakh
FY 2025 · +123% YoY
- Net Loss-₹3.6 Lakh
FY 2025 · -4% margin
- EBITDA-₹2.3 Lakh
FY 2025 · -2% margin
- Employee Count1
Associated legal entities of KoshKey
KoshKey operates through Koshkey Sciences Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Koshkey Sciences Private Limited CIN U73100KA2022PTC160768 | Active | 02 May 2022 | Bangalore, Karnataka | ₹1.0 Cr | – | 2 | View details |
Products & Services of KoshKey
KoshKey offers a comprehensive portfolio of products and services, including RNAi Therapy, Skin Biology Services, Histopathology Services, and Virology Services.
Therapy that silences genes to treat diabetic wounds and infections.
Provides analysis in skin biology and histopathology for medical studies.
Offers examination of tissue samples for disease research and treatment.
Conducts studies on viruses related to skin and wound infections.
Board of directors of Koshkey Sciences Private Limited (KoshKey)
Koshkey Sciences Private Limited is the primary company behind KoshKey. The board of Koshkey Sciences Private Limited currently have 2 directors; the longest-serving is Tanay Nitinkumar Bhatt, appointed in 2022. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Tanay Nitinkumar Bhatt DIN 09592649 | Director | 02 May 2022 | 4 yrs 5 mo | Koshkey Sciences Private Limited |
| Yogini Nitin Bhatt DIN 10542384 | Director | 28 Jun 2025 | 1 yr 3 mo | Koshkey Sciences Private Limited |
People of KoshKey
2 people are tracked at KoshKey (2 in leadership); the tracked headcount is 1.
| Name | Role | Group |
|---|---|---|
| Co-Founder | Leadership | |
Colin Jamora | Co-Founder | Leadership |
Complete people profiles for KoshKey
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of KoshKey
Figures of Koshkey Sciences Private Limited, the primary company behind KoshKey, for FY 2025. Revenue was ₹97.3 Lakh (+123% year on year). Net loss was -₹3.6 Lakh (-4% margin). EBITDA was -₹2.3 Lakh (-2% margin).
- ₹97.3 LakhRevenue · FY 2025 · +123% YoY
- -₹3.6 LakhNet loss · -4% margin
- -₹2.3 LakhEBITDA · -2% margin
- ₹1 LakhPaid-up capital
Balance sheet, profit and loss, cash flow and ratios of Koshkey Sciences Private Limited are on its company page.
Detailed financial statements for KoshKey
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of KoshKey
KoshKey operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MiRagen, ProQR Therapeutics, Prosensa, Cardior Pharmaceuticals and Ilya Pharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| proqr.com | 2012 | Leiden, Netherlands | $57.99M | – | RNA-based therapeutics are developed for genetic retinal disorders. | |
| prosensa.eu | 2002 | Leiden, Netherlands | $72.62M | – | RNA-modulating therapeutics for neuromuscular disorders were developed. | |
| cardior.de | 2016 | Hannover, Germany | $92.32M | – | Non-coding RNA therapeutics are developed for cardiovascular disease treatment. | |
| ilyapharma.se | 2016 | Uppsala, Sweden | $4.02M | – | Biological drugs for skin and mucosa wound treatment are developed. | |
| qbiotics.com | 2000 | Brisbane, Australia | $98.07M | – | Small molecules from plant extracts are developed for medical applications. | |
| mediwound.com | 2001 | Yavne, Israel | $18M | – | Enzymatic therapies for tissue repair and regeneration are developed. | |
| arthexbiotech.com | 2018 | Valencia, Spain | $93.61M | – | Oligonucleotide therapies for neuromuscular diseases like Myotonic Dystrophy are developed. | |
| exicuretx.com | 2009 | Skokie, United States | $72.29M | 13 | Gene silencing and immunomodulatory drugs are developed using SNA technology. | |
| resolution-tx.com | 2017 | Edinburgh, United Kingdom | $119.88M | 6 | Macrophage cell therapies are developed for inflammatory and liver diseases. |
Detailed competitors of KoshKey
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to KoshKey
10 companies that operate in the same segment as KoshKey (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about KoshKey
KoshKey was founded in 2022.
KoshKey is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
KoshKey has 1 employees.
The primary company behind KoshKey, Koshkey Sciences Private Limited, reported revenue of ₹97.3 Lakh for FY 2025, up 123% year on year.
KoshKey was founded in 2022 and is headquartered in Bengaluru, India. Gene therapies targeting antimicrobial-resistant skin infections are developed by the company within the biotechnology sector. RNAi-based treatments are provided, using technology that identifies genes linked to non-healing wounds in diabetic skin and silences them. Operations center on advancing therapies for persistent skin conditions in healthcare applications.
KoshKey's top competitors include Exicure, ProQR Therapeutics and Ilya Pharma.
KoshKey offers RNAi Therapy, Skin Biology Services, Histopathology Services, and Virology Services.
KoshKey operates through Koshkey Sciences Private Limited.
The legal entities of KoshKey currently have 2 directors, including Tanay Nitinkumar Bhatt, Yogini Nitin Bhatt.